← All trials
NCT00317629
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2006
- Primary completion
- Jan 1, 2009
- Completion date
- Mar 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 178
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fundación Cardiovascular de ColombiaLead sponsor
- Cardiovascular Foundation of ColombiaOverall official - principal investigator
- Akron UniversityOverall official - principal investigator
- University of AkronOverall official - principal investigator
- Fundación Cardiovascular de ColombiaStudy chair
- Universidad Industrial de SantanderStudy chair
- Cardiovascular Foundation of ColombiaStudy chair
- University of AkronStudy chair
- Universidad de AntioquiaStudy chair
- Universidad de AntioquiaCollaborator
- Universidad de SantanderCollaborator
- Secretaria de Salud de SantanderCollaborator
- Secretaria de Salud de TolimaCollaborator
- University of AkronCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.